 webinar on September 18, 2025, to discuss interim efficacy results from its ongoing Phase 2 study of ENV105, a first-in-class CD105 antagonist, in men with advanced prostate cancer.){kind=link}
Kairos Pharma, will host a Key Opinion Leader (KOL) webinar on September 18, 2025, to discuss interim efficacy results from its ongoing Phase 2 study of ENV105, a first-in-class CD105 antagonist, in men with advanced prostate cancer.
ENV105 is being investigated in combination with apalutamide, a standard androgen receptor inhibitor. The Phase 2 trial includes a safety lead-in followed by an efficacy evaluation. The interim efficacy analysis follows a safety update released in July 2025.
At that time, Kairos Pharma reported that ENV105 was well tolerated in the first 10 patients enrolled, with no dose-limiting toxicities, no Grade 3 or 4 treatment-related adverse events, and manageable side effects using standard supportive care.
The safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy results in treating prostate cancer patients. This predetermined efficacy analysis occurs four months after start of combination therapy of ENV105 and apalutamide in the last safety lead-in patient. We hope to lay out the primary benefits of our compound, and to clearly demonstrate the clinical need filled by ENV105. This distinguished panel of experts will provide participants with a renewed understanding of the importance of these data and the role ENV105 can have in targeting cancer drug resistance.
Dr. John Yu, CEO of Kairos Pharma.
Expert Panel
- Dr. Neil Bhowmick, President and Chief Scientific Officer, Kairos Pharma
- Dr. Umang Swami, Associate Professor of Oncology, Huntsman Cancer Institute
- Dr. Richard Lee, Clinical Co-Director, Genitourinary Cancers, Massachusetts General Hospital / Harvard Medical School
- Dr. Edwin Posadas, Director, Experimental Therapeutics Program, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute